ReviewNeuropsychiatric disease and treatment2017
Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.
Review in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Lorazepam in Managing Atypical Neuroleptic Malignant Syndrome: A Systematic Review of Case Reports.The western journal of emergency medicine · 2025Pooled it
- Neuroleptic malignant syndrome in a cervical spinal injury patient: a case report.Journal of trauma and injury · 2026Article
- Sertraline and quetiapine induced Serotonin Syndrome and Neuroleptic Malignant Syndrome: a case report.BMC psychiatry · 2026Article
- Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation.Journal of clinical medicine · 2025Review
- Dual Toxidrome of Anti-cholinergic Storm and Neuroleptic Malignant Syndrome: A Therapeutic Challenge Overcome by Intrathecal Neostigmine.The Neurohospitalist · 2024Article
- The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome.Scientific reports · 2023Article
- An Atypical Case of Neuroleptic Malignant Syndrome Associated With Ciprofloxacin and Quetiapine.Cureus · 2023Article
- Article
- Neuroleptic Malignant Syndrome in a Patient with Lithium-induced Nephrogenic Diabetes Insipidus: A Case Report.Indian journal of psychological medicine · 2023Article
- Multidisciplinary collaboration in diagnosis and treatment of neuroleptic malignant syndrome complicated with pneumonia: report of three cases.Diagnostic pathology · 2022Article
- Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.Journal of medical case reports · 2022Article
- Drug-Induced Hyperthermia Review.Cureus · 2022Review
- Clinical Practice Guidelines for Management of Medical Emergencies Associated with Psychotropic Medications.Indian journal of psychiatry · 2022Article
- A Case Report on Neuroleptic Malignant Syndrome (NMS): How to Approach an Early Diagnosis.Cureus · 2022Article
- Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases.BMC neurology · 2022Article
- A case of influenza-associated invasive aspergillosis with cerebral hemorrhage due to infectious vasculopathy.Radiology case reports · 2022Article
- Case Report: A Patient With Neuroleptic Malignant Syndrome, Water Intoxication and Hyponatremia Associated With Severe Cerebral Edema and Coma.Frontiers in endocrinology · 2022Article
- Neuroleptic Malignant Syndrome in Children with Autism Spectrum Disorder (ASD): A Case Report and Brief Review of Recent Literature.Children (Basel, Switzerland) · 2021Article
- Gluteal muscle damage and rhabdomyolysis after olanzapine poisoning: a case report.The Journal of international medical research · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. It is characterized by distinctive clinical features including a change in mental status, generalized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated properly. Mortality and morbidity attributed to this syndrome have recently declined markedly due to greater awareness, earlier diagnosis, and intensive care intervention. In most cases, the syndrome occurs as a result of a rapid increase in a dose of neuroleptic, especially one of the long-acting ones. Pathophysiology behind this syndrome is attributed to a dopamine receptor blockade inside the neurons rendered by the offending drug and excessive calcium release from the sarcoplasmic reticulum of skeletal myocytes. Laboratory tests, although not diagnostic, may assist in assessing the severity of the syndrome and also the consequent complications. The syndrome has been described in all age groups and occurs more in males than in females. Genetics appears to be central regarding the etiology of the syndrome. Stopping the use of the offending agent, cold intravenous fluids, and removal of the causative agent and its possible active metabolites is the cornerstone of treatment. Periodic observation of psychotic patients recently started on antipsychotic medications, especially those being treated with depot preparations, may aid to an early diagnosis of the syndrome and lead to early treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.